NCT00343109 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00343109/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
laboratory biomarker analysis [clinicaltrials_resource:5b31390aac23b9eac16b773d0b5e5031]leukapheresis [clinicaltrials_resource:9898de37ca11aac8b1e5c2626af4c362]sargramostim [clinicaltrials_resource:a99d28a200ff99670fa7105f4a87b571]HER-2/neu intracellular domain protein [clinicaltrials_resource:a9b052db710190135c7d88571335052b]immunologic technique [clinicaltrials_resource:ba614d84b726283350ab2271c80a2102]synthetic tumor-associated peptide vaccine therapy [clinicaltrials_resource:f741508e7fb772f8c9cdc08d0a10f82d]Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer [clinicaltrials:NCT00343109]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00343109 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00343109/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00343109/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
Patients receive HER-2/neu int ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:NCT00343109/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00343109 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00343109 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en